1111 related articles for article (PubMed ID: 19637418)
1. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
6. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
[TBL] [Abstract][Full Text] [Related]
7. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
Shao LM; Chen MY; Cai JT
Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
[TBL] [Abstract][Full Text] [Related]
11. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
13. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Sandborn WJ; Schreiber S; Hanauer SB; Colombel JF; Bloomfield R; Lichtenstein GR;
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):696-702.e1. PubMed ID: 20363366
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
Abreu MT
Rev Gastroenterol Disord; 2007; 7 Suppl 1():S20-6. PubMed ID: 17392630
[TBL] [Abstract][Full Text] [Related]
19. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol: in Crohn's disease.
Blick SK; Curran MP
BioDrugs; 2007; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]